MAGNETOM RT Pro edition for MAGNETOM Vida
The time is now for MR in RT – with BioMatrix.
MRI utilization in radiation therapy treatment planning has grown steadily between 2006 and 2017: from 6% to 25%1. MRI offers excellent soft tissue contrast without radiation dose, making it ideal for RT purposes where CT information can be enriched with valuable MRI information. The MAGNETOM RT Pro edition for MAGNETOM Vida can expand your clinical capabilities in radiation therapy planning.
Whether for primary brain tumors or intracranial metastases, MRI provides vital imaging information to support treatment planning of conventional and stereotactic radiotherapy. With the RT Dot Engine, we provide dedicated RT protocols for brain and head/neck exams, enabling visualization for physicians to assess the extent of the lesion and potential side effects, such as edema and necrosis. The protocols are optimized for imaging in the treatment position with flexible Tim 4G coils that enable reliable simulation of the treatment situation. New ultra-high-density coils like the UltraFlex 18 improve SNR and allow for high spatial resolution in shorter exam times.
Head & Neck
When treating head/neck tumors, MRI can provide valuable information about the soft tissue structures. However, in this region, image quality and spatial integrity of the acquired data often is compromised by spatial distortions, motion, and susceptibility effects. The new BioMatrix platform, with unique techniques like SliceAdjust, helps achieve images of high spatial integrity and high signal homogeneity for RT planning purposes.
In radiation therapy of the prostate, the volume of the organ is often overestimated when using CT only2. MRI delivers excellent soft tissue contrast and can offer a more precise delineation of the prostate and organs at risk. With multi-parametric MRI (diffusion-weighted imaging and spectroscopy), you can even see metabolically active regions of a tumor that could help you identify regions for dose escalation and enable tailored treatment planning to drive better therapeutic outcomes3.
With RESOLVE, diffusion-weighted imaging has been performed with significantly better lesion conspicuity and image quality4, and typical distortions were reduced by a factor of three5. It is the DWI sequence of choice for accurate target delineation6*.
For cervical cancers treated with brachytherapy, the EMBRACE study has shown that the ability of MRI to visualize and delineate soft tissue supports improved target coverage and may spare normal tissue7. With fast isotropic 3D sequences, like SPACE or VIBE, along with 3D distortion correction, you can acquire excellent planning data for the therapy process. Various contrasts for reliable 3D planning in brachytherapy (e.g., T1, T2, and PD) are available.
1IMV 2013/14 Radiation; Therapy Market Summary Report.
2Van Lin et al. IJROBP 2006;65:291–303
3Kuban et al. IJROBP 2011;79:1310-1317
4Thian et al. Academic Radiology, 2014:21(4)
5Foltz, et al. IJRO 2013
6Liney et al. MAGNETOM Flash 2014:59-13-17
7Pötter R., Radiother Oncol. 2011; 100(1): 116–123
*The statements by the customer described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption), there can be no guarantee that other customers will achieve the same results.